In this issue:
REGENCY: obinutuzumab in lupus nephritis
Oral mizoribine vs. intravenous cyclophosphamide as induction therapy
TULIP-LTE: patient-reported outcomes with anifrolumab in SLE
Risk factors for low BMD & osteoporosis in SLE
Swedish trends in glucocorticoid & hydroxychloroquine use in SLE
Physical activity & risk of SLE
Kidney function with SGLT2 inhibitors in SLE
Recombinant zoster vaccine in SLE
Safety of mycophenolate mofetil in SLE
Please login below to download this issue (PDF)